Annual results show a structure of continuing sales declines alongside operating losses that have persisted for four consecutive years.
Sales fell from KRW 80.6 billion in 2022 to KRW 24.5 billion in 2023 (down 69.6 percent year on year), KRW 8.81 billion in 2024 (down 64.1 percent), and KRW 6.51 billion in 2025 (down 26.1 percent), a three-year decline from 2023 through 2025; 2022 was the largest year and 2025 the smallest in the 2022 to 2025 period.
Operating loss widened from KRW 2.78 billion in 2022 to KRW 6.79 billion in 2023, then narrowed to KRW 3.22 billion in 2024 and KRW 2.82 billion in 2025. However, the operating margin moved from -3.4 percent in 2022 to -27.7 percent in 2023, -36.5 percent in 2024, and -43.4 percent in 2025.
Because the sales decline outpaced the reduction in losses, the margin worsened even in 2024 and 2025, when the absolute loss shrank. Press reports attribute the 2025 operating loss to selling, general and administrative expenses exceeding gross profit, with sales commissions the largest SG&A item.
Net results differ depending on the basis. Net loss attributable to controlling shareholders was KRW 13.9 billion in 2022, KRW 149 million in 2023, KRW 5.71 billion in 2024, and KRW 16.8 billion in 2025, a loss for four consecutive years from 2022 to 2025.
Net income including non-controlling interests was a net loss of KRW 13.6 billion in 2022, net income of KRW 142 million in 2023, a net loss of KRW 5.72 billion in 2024, and a net loss of KRW 16.8 billion in 2025, so 2023 was the only profitable year on that basis.
Press reports say the company expensed KRW 10.8 billion of investment costs at the end of 2025, including an impairment on its stake in subsidiary BL Melanics and losses on equity-method investments, and cite these charges as the main reason for the 2025 net loss.
Quarterly results began with Q3 2025 sales of KRW 907 million and an operating loss of KRW 503 million. Q4 2025 sales were KRW 810 million (down 10.6 percent from the prior quarter), with an operating loss of KRW 1.14 billion and a controlling-shareholder net loss of KRW 13.8 billion.
Q1 2026 sales rose to KRW 1.52 billion (up 87.1 percent from the prior quarter) and operating profit was KRW 49.06 million, a swing to profit. Q2 2026 posted an operating loss of KRW 1.34 billion, a return to loss, and a controlling-shareholder net loss of KRW 1.66 billion.
Q3 2026 sales were KRW 1.12 billion (up 23.4 percent year on year), operating profit was KRW 32.45 million, a swing to profit from a year earlier, and the controlling-shareholder net loss narrowed to KRW 207 million from the prior quarter and the prior-year quarter.
The controlling-shareholder net loss for the last four quarters (Q4 2025 to Q3 2026) totaled KRW 15.2 billion; because the gap between operating results and controlling-shareholder results is wide, the composition of non-operating items is the next item to check.
At end-2025 total equity was KRW 7.93 billion (KRW 7.9 billion attributable to controlling shareholders), total liabilities were KRW 10.3 billion, and the debt ratio rose to 129.5 percent from 50.2 percent in 2024.
Operating cash flow was -KRW 11 billion in 2022, KRW 7.99 billion in 2023, -KRW 3.04 billion in 2024, and -KRW 284 million in 2025.